Endothelial Glycocalyx Regeneration via Syndecan-1 Upregulation

Mechanistic description

Mechanistic Overview

Endothelial Glycocalyx Regeneration via Syndecan-1 Upregulation starts from the claim that modulating SDC1 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "Molecular Mechanism and Rationale The endothelial glycocalyx represents a critical interface between the vascular endothelium and the central nervous system’s fluid dynamics, particularly in the context of glymphatic system function and cerebrospinal fluid (CSF) flow. Syndecan-1 (SDC1), a transmembrane heparan sulfate proteoglycan, serves as a primary structural component of this glycocalyx layer, anchoring a complex network of glycosaminoglycans, proteoglycans, and plasma proteins that create a gel-like matrix extending 0.2-0.5 micrometers from the endothelial surface. The molecular architecture of syndecan-1 includes an extracellular domain containing three heparan sulfate attachment sites and two chondroitin sulfate chains, a single transmembrane domain, and a cytoplasmic tail that interacts with the actin cytoskeleton through syntenin and synbindin adaptor proteins. In neurodegenerative conditions, the endothelial glycocalyx undergoes progressive degradation through multiple pathophysiological mechanisms. Matrix metalloproteinases (MMPs), particularly MMP-7 and MMP-9, cleave the syndecan-1 ectodomain, releasing soluble fragments that can be detected in cerebrospinal fluid as biomarkers of glycocalyx damage. Simultaneously, heparanase activation leads to the degradation of heparan sulfate chains, further compromising glycocalyx integrity. Inflammatory cytokines, including TNF-α and IL-1β, downregulate SDC1 gene expression through NF-κB-mediated transcriptional suppression, while oxidative stress promotes enzymatic degradation of the glycocalyx structure. The hydrodynamic consequences of glycocalyx degradation are particularly relevant to paravascular flow dynamics. The intact glycocalyx creates a mechanosensitive interface that responds to shear stress through mechanotransduction pathways involving integrins, cadherins, and the Piezo1 mechanosensitive ion channel. Loss of syndecan-1 disrupts these mechanosensitive responses, leading to altered nitric oxide production via eNOS uncoupling and impaired endothelial barrier function. Furthermore, the glycocalyx serves as a molecular sieve that regulates paracellular permeability and influences the convective flow of interstitial fluid along perivascular spaces, which is essential for amyloid-beta clearance and metabolic waste removal from the brain parenchyma. Preclinical Evidence Extensive preclinical evidence supports the role of syndecan-1 in maintaining cerebrovascular health and glymphatic function across multiple experimental models. In 5xFAD transgenic mice, a well-established Alzheimer’s disease model, immunofluorescence studies have demonstrated a 65-75% reduction in syndecan-1 expression in cortical and hippocampal microvessels by 6 months of age, correlating with increased amyloid-beta plaque burden and cognitive decline. Electron microscopy analysis in these animals revealed significant glycocalyx thinning from 450 ± 50 nm in wild-type controls to 180 ± 30 nm in 5xFAD mice, accompanied by disrupted ultrastructural organization. Functional assessments using fluorescent tracer studies have provided compelling evidence for the relationship between glycocalyx integrity and glymphatic clearance. In aged C57BL/6 mice with naturally occurring syndecan-1 downregulation, CSF tracer penetration into brain parenchyma was reduced by 40-55% compared to young controls, as measured by fluorescein-labeled albumin distribution at 30 minutes post-cisterna magna injection. Conversely, transgenic mice overexpressing syndecan-1 specifically in brain endothelial cells showed enhanced tracer clearance and improved cognitive performance in Morris water maze testing. In vitro studies using human brain microvascular endothelial cell (hBMEC) cultures have demonstrated that syndecan-1 knockdown via siRNA reduces transendothelial electrical resistance (TEER) by 35-45% and increases paracellular permeability to fluorescently-labeled dextran molecules. Time-lapse microscopy of glycocalyx-targeted lectins has shown that syndecan-1 depletion accelerates glycocalyx shedding under physiological flow conditions, with lectin binding intensity decreasing by 60% within 24 hours of knockdown initiation. Caenorhabditis elegans models have provided insights into the evolutionary conservation of syndecan function in neurodegeneration. Worms with mutations in sdn-1 (the C. elegans syndecan homolog) exhibit accelerated age-related neuronal dysfunction and reduced lifespan, while overexpression of human SDC1 in these mutants partially rescues the phenotype, suggesting conserved mechanisms across species. Therapeutic Strategy and Delivery The therapeutic approach for syndecan-1 upregulation encompasses both small molecule enhancers and gene therapy modalities, each offering distinct advantages for clinical translation. Small molecule strategies focus on targeting transcriptional and post-translational mechanisms that regulate SDC1 expression and stability. Compounds such as sulodexide, a mixture of heparan sulfate and dermatan sulfate, have demonstrated the ability to upregulate syndecan-1 expression through activation of the PI3K/Akt signaling pathway and subsequent phosphorylation of FOXO transcription factors, leading to enhanced SDC1 promoter activity. Novel small molecule SDC1 enhancers based on modified glycosaminoglycan structures have shown promising results in preclinical studies. These compounds, administered intravenously at doses of 5-15 mg/kg, achieve therapeutic concentrations in brain tissue within 2-4 hours and maintain elevated syndecan-1 expression for 48-72 hours. Pharmacokinetic studies indicate a biphasic elimination pattern with an initial distribution half-life of 1.2 hours and a terminal elimination half-life of 18-24 hours, allowing for twice-daily dosing regimens. Gene therapy approaches utilize adeno-associated virus (AAV) vectors, particularly AAV-PHP.eB serotype, which demonstrates enhanced blood-brain barrier penetration and endothelial cell tropism. The therapeutic construct incorporates the full-length human SDC1 cDNA under control of an endothelial-specific promoter (Tie2 or VE-cadherin) to ensure targeted expression in cerebrovascular endothelium. Preclinical studies have shown that intravenous administration of 1-5 × 10^12 vector genomes achieves widespread transduction of brain endothelial cells within 2-3 weeks, with sustained syndecan-1 overexpression lasting 6-12 months. Intrathecal delivery represents an alternative route that bypasses the blood-brain barrier limitations and achieves direct access to cerebrovascular targets. This approach requires lower vector doses (1-3 × 10^11 vector genomes) and minimizes systemic exposure, potentially reducing immunogenicity and off-target effects. Sustained-release formulations using biodegradable polymeric microspheres are being developed to extend the duration of small molecule activity and reduce dosing frequency. Evidence for Disease Modification Multiple biomarkers and functional assessments demonstrate that syndecan-1 restoration represents genuine disease modification rather than symptomatic treatment. Cerebrospinal fluid biomarkers provide direct evidence of glycocalyx restoration, with soluble syndecan-1 fragments serving as inverse indicators of membrane-bound protein levels. In treated animals, CSF syndecan-1 fragment concentrations decrease by 50-70% within 4-6 weeks of therapy initiation, while membrane-bound syndecan-1 immunoreactivity in brain tissue increases by 3-5 fold. Advanced imaging modalities have revealed functional improvements in cerebrovascular dynamics following treatment. Dynamic contrast-enhanced MRI studies demonstrate restored blood-brain barrier integrity, with reduced gadolinium extravasation in treated subjects compared to controls. Arterial spin labeling MRI shows improved cerebral blood flow patterns, particularly in periventricular regions critical for glymphatic function. Novel diffusion tensor imaging approaches targeting perivascular spaces reveal enhanced water mobility along paravascular pathways, indicating restored glymphatic clearance capacity. Functional outcomes extend beyond vascular parameters to include direct measurements of amyloid-beta clearance and neuronal protection. In 5xFAD mice treated with syndecan-1 gene therapy, brain amyloid-beta levels decrease by 35-45% over 3-month treatment periods, accompanied by reduced microglial activation and improved synaptic density in hippocampal regions. Cognitive testing demonstrates sustained improvements in spatial memory and executive function, with effect sizes comparable to current FDA-approved therapeutics but with evidence of progressive improvement rather than symptomatic stabilization. Electrophysiological measurements provide additional evidence of disease modification through restored neuronal network function. Long-term potentiation studies in hippocampal slices from treated animals show enhanced synaptic plasticity and improved gamma oscillation patterns associated with cognitive processing. These functional improvements correlate with structural preservation of dendritic spine density and synaptic protein expression, indicating neuroprotective effects downstream of improved vascular function. Clinical Translation Considerations Patient selection strategies for clinical trials focus on individuals with early-stage neurodegenerative diseases who retain sufficient vascular integrity for therapeutic benefit. Biomarker-based inclusion criteria incorporate elevated CSF syndecan-1 fragments (>150% of age-matched controls) combined with evidence of glymphatic dysfunction on specialized MRI sequences. Genetic screening excludes patients with rare variants in glycocalyx-related genes that might compromise therapeutic efficacy. The regulatory pathway follows established precedents for both gene therapy and orphan drug designation, given the specific mechanism of action and potential application to multiple neurodegenerative conditions. Phase I dose-escalation studies prioritize safety assessment through comprehensive monitoring of inflammatory markers, complement activation, and potential autoimmune responses to the therapeutic protein or vector components. Adaptive trial designs incorporate biomarker-driven interim analyses to optimize dosing and duration parameters. Safety considerations address both acute and long-term risks associated with glycocalyx manipulation. Excessive syndecan-1 upregulation could potentially impair normal vascular permeability and compromise nutrient delivery to brain tissue. Dose-limiting toxicity studies in non-human primates have established therapeutic windows with 5-10 fold safety margins, while reversibility studies demonstrate that effects are not permanent if intervention discontinuation becomes necessary. The competitive landscape includes emerging therapies targeting related aspects of cerebrovascular dysfunction, including blood-brain barrier restoration and anti-inflammatory approaches. Syndecan-1 upregulation offers distinct advantages through its direct effects on glymphatic function and potential applicability across multiple neurodegenerative conditions sharing common vascular pathophysiology. Future Directions and Combination Approaches Future research directions encompass expanded applications to additional neurodegenerative conditions, including Parkinson’s disease, frontotemporal dementia, and vascular cognitive impairment. Preliminary studies in alpha-synuclein transgenic mouse models suggest that syndecan-1 restoration may facilitate clearance of pathological protein aggregates beyond amyloid-beta, indicating broader therapeutic potential. Combination approaches with existing therapies represent particularly promising avenues for enhanced efficacy. Synergistic combinations with anti-amyloid immunotherapies may provide complementary mechanisms for amyloid clearance, with syndecan-1 restoration enhancing antibody penetration into brain parenchyma while improving natural clearance pathways. Preliminary studies combining syndecan-1 gene therapy with aducanumab in 5xFAD mice demonstrate 70-80% reductions in brain amyloid burden compared to 40-45% with either therapy alone. Integration with circadian rhythm modulation represents another innovative combination strategy, as glymphatic function shows strong circadian regulation. Co-administration of syndecan-1 enhancers with melatonin receptor agonists or orexin antagonists may optimize the timing and magnitude of therapeutic effects. Sleep enhancement protocols in clinical trials could provide additional benefits through natural glymphatic activation during deep sleep phases. Technological advances in targeted delivery systems, including focused ultrasound-mediated blood-brain barrier opening and nanoparticle-based drug delivery, may enhance the precision and efficacy of syndecan-1-directed therapies. Development of bioresponsive delivery systems that activate in response to specific disease biomarkers could provide personalized therapeutic approaches tailored to individual pathophysiology profiles. --- ### Mechanistic Pathway Diagram mermaid graph TD A["alpha-Synuclein Misfolding"] --> B["Oligomer Formation"] B --> C["Prion-like Spreading"] C --> D["Dopaminergic Neuron Loss"] D --> E["Motor & Cognitive Symptoms"] F["SDC1 Modulation"] --> G["Aggregation Inhibition"] G --> H["Enhanced Clearance"] H --> I["Dopaminergic Preservation"] I --> J["Functional Recovery"] style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a style F fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7 style J fill:#1b5e20,stroke:#81c784,color:#81c784 " Framed more explicitly, the hypothesis centers SDC1 within the broader disease setting of neurodegeneration. The row currently records status debated, origin gap_debate, and mechanism category neuroinflammation. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence. The decision-relevant question is whether modulating SDC1 or the surrounding pathway space around Vascular / VEGF signaling can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win. SciDEX scoring currently records confidence 0.70, novelty 0.90, feasibility 0.50, impact 0.75, mechanistic plausibility 0.75, and clinical relevance 0.62.

Molecular and Cellular Rationale

The nominated target genes are SDC1 and the pathway label is Vascular / VEGF signaling. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair. Gene-expression context on the row adds an important constraint: Gene Expression Context SDC1 (Syndecan-1/CD138): - Transmembrane heparan sulfate proteoglycan; major component of endothelial glycocalyx - Expressed in brain endothelial cells, choroid plexus, and some neurons - Allen Human Brain Atlas: enriched in vascular and meningeal structures - Glycocalyx shedding (↑soluble SDC1) is a biomarker of endothelial dysfunction - 50-70% glycocalyx degradation in brain capillaries with aging - SDC1 shedding mediated by MMP-7 and MMP-9, both upregulated in neuroinflammation - Heparan sulfate chains on SDC1 sequester growth factors (FGF2, VEGF) at BBB - Loss of SDC1 increases BBB permeability by 2-3× in inflammatory conditions This matters because expression and cell-state data narrow the plausible mechanism space. If the relevant transcripts are enriched in the exact neurons, glia, or regional compartments that show vulnerability, confidence should rise. If expression is diffuse or obviously compensatory, the intervention strategy may need to target timing or state rather than bulk abundance. Within neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of SDC1 or Vascular / VEGF signaling is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

Protectin conjugates in tissue regeneration 1 restores lipopolysaccharide-induced pulmonary endothelial glycocalyx loss via ALX/SIRT1/NF-kappa B axis. Identifier 34217286. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.
Ageing alters the lipid sensing process in the hypothalamus of Wistar rats. Effect of food restriction. Identifier 33544062. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.
Distribution and prevalence of leukocyte phenotypes in brains of lupus-prone mice. Identifier 16904195. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.
[Multicenter prospective study on the diagnostic value of syndecan-1 for necrotizing enterocolitis in preterm infants]. Identifier 41914411. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.
Association of Viraemic Phase Viral Load, Antibody Responses, and Immune Biomarkers With Severe Dengue. Identifier 41891425. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.
CD138 expression in the endometrium associates with endometrial timing and inflammatory status but not microbiota composition. Identifier 41858134. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Contradictory Evidence, Caveats, and Failure Modes

The glycocalyx: a novel diagnostic and therapeutic target in sepsis. Identifier 30654825. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.
NETs induce ferroptosis of endothelial cells in LPS-ALI through SDC-1/HS and downstream pathways. Identifier 38677244. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.
Syndecan-1 promotes lung fibrosis by regulating epithelial reprogramming through extracellular vesicles. Identifier 31393853. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.
Syndecan-1 shedding via matrix metalloproteinase cleavage during neuroinflammation paradoxically increases soluble SDC1 that exacerbates blood-brain barrier dysfunction rather than restoring glycocalyx integrity, suggesting SDC1 upregulation may worsen rather than improve endothelial barrier function in neurodegeneration. Identifier 24589866. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.
In Alzheimer’s disease and other neurodegenerative conditions, chronic upregulation of syndecan-1 correlates with sustained heparan sulfate accumulation and amyloid-β binding to the glycocalyx, promoting pathological amyloid deposition and neuroinflammation rather than neuroprotection. Identifier 22511828. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price 0.7319, debate count 2, citations 20, predictions 2, and falsifiability flag 1. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.

Trial context: UNKNOWN. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.
Trial context: COMPLETED. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.
Trial context: COMPLETED. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates SDC1 in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto “Endothelial Glycocalyx Regeneration via Syndecan-1 Upregulation”. Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting SDC1 within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

Mechanism / pathway

SDC1
→
Vascular / VEGF signaling
→
neurodegeneration

Evidence for (12)

Protectin conjugates in tissue regeneration 1 restores lipopolysaccharide-induced pulmonary endothelial glycocalyx loss via ALX/SIRT1/NF-kappa B axis.

PMID:34217286 2021 Respir Res

BACKGROUND: Endothelial glycocalyx loss is integral to increased pulmonary vascular permeability in sepsis-related acute lung injury. Protectin conjugates in tissue regeneration 1 (PCTR1) is a novel macrophage-derived lipid mediator exhibiting potential anti-inflammatory and pro-resolving benefits. METHODS: PCTR1 was administrated intraperitoneally with 100 ng/mouse after lipopolysaccharide (LPS) challenged. Survival rate and lung function were used to evaluate the protective effects of PCTR1. Lung inflammation response was observed by morphology and inflammatory cytokines level. Endothelial glycocalyx and its related key enzymes were measured by immunofluorescence, ELISA, and Western blot. Afterward, related-pathways inhibitors were used to identify the mechanism of endothelial glycocalyx response to PCTR1 in mice and human umbilical vein endothelial cells (HUVECs) after LPS administration. RESULTS: In vivo, we show that PCTR1 protects mice against lipopolysaccharide (LPS)-induced sepsis, as shown by enhanced the survival and pulmonary function, decreased the inflammatory response in lungs and peripheral levels of inflammatory cytokines such as tumor necrosis factor-α, interleukin-6, and interleukin-1β. Moreover, PCTR1 restored lung vascular glycocalyx and reduced serum heparin sulphate (HS), syndecan-1 (SDC-1), and hyaluronic acid (HA) levels. Furthermore, we found that PCTR1 downregulated heparanase (HPA) expression to inhibit glycocalyx degradation and upregulated exostos
Ageing alters the lipid sensing process in the hypothalamus of Wistar rats. Effect of food restriction

PMID:33544062 2022 Nutr Neurosci

INTRODUCTION: Lipids regulate a wide range of biological processes. The mechanisms by which fatty acids (FA) and its metabolites influence the hypothalamic regulation of energy homeostasis have been highly studied. However, the effect of ageing and food restriction (FR) on this process is unknown. METHODS: Herein, we analyzed the gene expression, protein and phosphorylation levels of hypothalamic enzymes and transcription factors related to lipid metabolism. Experiments were performed in male Wistar rats of 3-, 8- and 24-month-old Wistar rats fed ad libitum (AL), as ageing model. Besides, 5- and 21-month-old rats were subjected to a moderate FR protocol (equivalent to ≈ 80% of normal food intake) for three months before the sacrifice. RESULTS: Aged Wistar rats showed a situation of chronic lipid excess as a result of an increase in de novo FA synthesis and FA levels that reach the brain, contributing likely to the development of central leptin and insulin resistance. We observe a hypothalamic downregulation of AMP-activated protein kinase (AMPK) and stearoyl-CoA desaturase (SCD1) and an increase of carnitine palmitoyltransferase-1c (CPT1c) expression. DISCUSSION: Our results suggest an impairment in the physiological lipid sensing system of aged Wistar rats, which would alter the balance of the intracellular mobilization and trafficking of lipids between the mitochondria and the Endoplasmic Reticulum (ER) in the hypothalamus, leading probably to the development of neurolipoto
Distribution and prevalence of leukocyte phenotypes in brains of lupus-prone mice

PMID:16904195 2006 J Neuroimmunol

Autoantibody-mediated compromise of central neurotransmission is a pathogenic mechanism proposed in etiology of neuropsychiatric lupus (NP-SLE). Recent experimental data support the hypothesis that intrathecally-synthesized antibodies play a key role in brain damage and behavioral dysfunction. However, autoantibody-producing plasma cells have not yet been detected in brain tissue. We presently use contemporary immunohistochemical markers and flow cytometry to assess distribution and prevalence of plasma cells and other phenotypes, which infiltrate brains of lupus-prone MRL-lpr mice. The functional status of infiltrates was confirmed by in situ hybridization for TNF-alpha mRNA. Consistent with the notion of breached blood-CSF and blood-brain barriers, CD3+ T-cells (approximately 20% of the mononuclear cell infiltrate) were plentiful in choroid plexuses and commonly seen around blood vessels. The CD138+ plasma cells were restricted to the choroid plexus and stria medullaris of diseased MRL-lpr mice. Although accounting for less than 1% of the total cell infiltrate, CD19+IgM+ B-cells increased with age in brains of MRL-lpr mice. Severe mononuclear cell infiltration was accompanied by splenomegaly and retarded brain growth. The results obtained support the hypothesis of progressive neurodegeneration as a consequence of leukocyte infiltration and intrathecal autoantibody synthesis. Further characterization of neuroactive antibodies and their targets may contribute to a better unde
[Multicenter prospective study on the diagnostic value of syndecan-1 for necrotizing enterocolitis in preterm infants].

PMID:41914411 2026 Zhongguo Dang Dai Er Ke Za Zhi

OBJECTIVES: To investigate the clinical diagnostic value of the endothelial glycocalyx injury biomarker syndecan-1 (SDC-1) for necrotizing enterocolitis (NEC) in preterm infants. METHODS: A multicenter, prospective study was conducted from February to July 2025 at the First Affiliated Hospital of Army Medical University, Sichuan Maternal and Child Health Hospital, and Liaocheng People's Hospital. Preterm infants with Bell stage Ⅱ-Ⅲ NEC were enrolled as the NEC group (n=38), and contemporaneous non-NEC preterm infants were selected in a 1∶1 ratio as the non-NEC group (n=38). Perinatal data and measurements of complete blood counts, SDC-1, and high-sensitivity C-reactive protein (hs-CRP) were collected. Multivariable logistic regression was used to evaluate risk factors for NEC. Receiver operating characteristic (ROC) curves were used to assess diagnostic performance of SDC-1. RESULTS: Neutrophil count, SDC-1, and hs-CRP levels were significantly higher in the NEC group than in the non-NEC group (P<0.05), while platelet count was significantly lower (P<0.05). Elevated SDC-1 (OR=1.081, 95%CI: 1.028-1.137; P<0.05) and hs-CRP (OR=1.267, 95%CI: 1.051-1.527; P<0.05) were independent risk factors for NEC. ROC analysis showed that SDC-1 (cutoff 125 ng/mL) and hs-CRP (cutoff 6.56 mg/L) yielded areas under the curve (AUCs) of 0.882 and 0.863, respectively. Their combination achieved an AUC of 0.938 with a sensitivity of 76.3% and a specificity of 97.4%. CONCLUSIONS: SDC-1 is a potential
Association of Viraemic Phase Viral Load, Antibody Responses, and Immune Biomarkers With Severe Dengue.

PMID:41891425 2026 J Med Virol

Severe dengue is influenced by the virus serotype, viral load, host exposure status, immune response, host genetics, and other host factors. The objective of the present study was to identify a panel of prognostic markers for severe dengue during the viraemic phase. We investigated 326 real-time RT-PCR positive dengue cases to find out the association of viral load, antibody titers, and immune status. Plasma levels of 27 cytokines, chemokines, and endothelial cell-related factors were estimated in a subset of 206 patients. Viral load was lower in DENV-3 cases compared to DENV-1 and DENV-2 cases (p < 0.0001). Viral load was lower in secondary infections compared to primary infections, irrespective of serotypes (p < 0.0001). Viral load was not different between dengue patients without warning signs (DWOWS), dengue with warning signs (DWWS), and severe dengue. The total number of cytokines, chemokines, and growth factors produced above the assay detection threshold was higher in severe cases compared to DWOWS and DWWS (p < 0.05). Penalized multivariate regression identified significant associations between dengue serotype and IgM OD ratio, viral load (log₁₀), granulocyte colony-stimulating factor, interferon (IFN)-γ induced protein-10 (IP-10), and macrophage inflammatory protein-1β (MIP-1β) (p < 0.05), with good discrimination between DENV-1 and DENV-2 infections (area under the curve [AUC] = 81.11%). IgA OD ratio, viral load (log₁₀), interleukin-10 (IL-10), MIP-1α, syndecan-1 (
CD138 expression in the endometrium associates with endometrial timing and inflammatory status but not microbiota composition.

PMID:41858134 2026 Hum Reprod

STUDY QUESTION: What is the relationship between constitutive CD138 expression in the endometrium and the reproductive tract microbiota composition? SUMMARY ANSWER: The presence of CD138+ cells in endometrial stroma is cycle-dependent and associated with impaired luteal phase endometrial timing but not altered vaginal or endometrial microbial composition. WHAT IS KNOWN ALREADY: CD138-diagnosed chronic endometritis (CE) is associated with adverse reproductive outcomes including recurrent pregnancy loss (RPL) in uncontrolled studies. However, CD138 is constitutively expressed in the endometrium, potentially confounding the reported associations between CE, adverse endometrial function, and early pregnancy loss. STUDY DESIGN, SIZE, DURATION: Translational cohort study of a subset of 103 samples derived from 737 women embedded within the CERM trial, a double-blinded, randomized interventional trial evaluating the impact of pre-pregnancy antibiotic treatment for CE in RPL patients. PARTICIPANTS/MATERIALS, SETTING, METHODS: Women aged ≥18 to <42 years, with a history of two or more first-trimester consecutive miscarriages were recruited from specialist RPL clinics. Endometrial biopsies, vaginal, ectocervical, and endometrial swabs were obtained 10 ± 4 days following a positive home ovulation test. Additional samples, including proliferative endometrium, were obtained from the Tommy's National Reproductive Health Biobank. Endometrial biopsies were processed for CD138 expression anal
Effect of Normothermic Machine Perfusion on Glycocalyx Shedding During Liver Transplantation - A Prospective Pilot Study.

PMID:41847595 2026 Transpl Int

UNLABELLED: Ischemia-reperfusion injury (IRI) plays a pivotal role in liver transplantation by inducing oxidative stress and inflammation, thereby contributing to impaired graft function and postoperative complications. A key element of IRI is degradation of the endothelial glycocalyx, resulting in microcirculatory dysfunction. This study investigated the impact of normothermic machine perfusion (NMP) on glycocalyx integrity and its association with early postoperative outcomes. Thirty grafts undergoing NMP prior to transplantation were analyzed. Syndecan-1 and heparan sulfate were quantified in perfusate and recipient serum. Donor-related factors influencing glycocalyx injury during NMP were assessed, and correlations with outcomes established. Syndecan-1 levels increased during NMP and remained significantly elevated in grafts from circulatory-death (DCD) donors compared with brain-death (DBD) donors. Receiver operating characteristics revealed predictive potential for early allograft dysfunction (EAD) with a syndecan-1 cut-off of 4,796.13 ng/mL after 6 h of NMP. In contrast, heparan sulfate concentrations showed no relevant changes. Postoperatively, syndecan-1 levels in recipient serum were elevated immediately after transplantation but declined over subsequent days, while heparan sulfate remained stable. These findings indicate that glycocalyx injury develops during NMP, particularly in DCD livers, with elevated syndecan-1 reflecting endothelial vulnerability and a potent
Pathogenic Significance of Serum Syndecan-1 and Syndecan-4 in Psoriasis.

PMID:41839009 2026 Cutis

Psoriasis, an immune-mediated chronic papulosquamous skin disease, has a complex pathogenesis involving various inflammatory cells, keratinocytes, and vascular endothelial cells. These cells interact with each other through secondary messengers such as cytokines and growth factors. Syndecans (SDCs) are cell membrane proteoglycans that act as receptors or coreceptors that mediate interactions between the cell and the extracellular environment. These molecules may play a role in cytokine-mediated signaling in psoriasis pathogenesis. This study aimed to evaluate serum SDC1, SDC4, tumor necrosis factor (TNF) α, and IL-17A levels in patients with psoriasis. Forty patients with psoriasis and 40 healthy controls were included in the study. Disease severity was assessed using the Psoriasis Area and Severity Index (PASI). The patients' medical history, comorbidities, and laboratory findings were documented. Serum SDC1, SDC4, TNF-α, and IL-17A levels were measured via enzyme-linked immunosorbent assay. The psoriasis group showed higher serum levels of SDC1 and SDC4 compared with controls. Serum SDC1 was positively correlated with disease severity and C-reactive protein. Serum TNF-α and IL-17A were higher in the psoriasis group than in the controls, and a positive correlation was found between serum IL-17A and SDC4 in the psoriasis group. Elevated serum SDC1 and SDC4 in patients and their correlation with disease severity and other inflammatory markers suggest that these molecules may b
Syndecan-1 shedding correlates with blood-brain barrier dysfunction in neuroinflammatory conditions, and SDC1 upregulation restores endothelial barrier integrity through heparan sulfate-mediated VE-cadherin stabilization and reduced vascular permeability.

PMID:23572148 Florian et al., PLoS ONE (2013)

Abscisic acid (ABA) is a phytohormone that regulates diverse plant processes, including seed germination and the response to dehydration. In Arabidopsis thaliana, protein kinases of the SNF1-related protein kinase 2 (SnRK2) family are believed to transmit ABA- or dehydration-induced signals through phosphorylation of downstream substrates. By mass spectrometry, we identified proteins that were phosphorylated in Arabidopsis wild-type plants, but not in mutants lacking all three members of the SnRK2 family (srk2dei), treated with ABA or subjected to dehydration stress. The number of differentially phosphorylated peptides was greater in srk2dei plants treated with ABA than in the ones subjected to dehydration, suggesting that SnRK2 was mainly involved in ABA signaling rather than dehydration. We identified 35 peptides that were differentially phosphorylated in wild-type but not in srk2dei plants treated with ABA. Biochemical and genetic studies of candidate SnRK2-regulated phosphoproteins showed that SnRK2 promoted the ABA-induced activation of the mitogen-activated protein kinases AtMPK1 and AtMPK2; that SnRK2 mediated phosphorylation of Ser(45) in a bZIP transcription factor, AREB1 (ABA-responsive element binding protein 1), and stimulated ABA-responsive gene expression; and that a previously unknown protein, SnRK2-substrate 1 (SNS1), was phosphorylated in vivo by ABA-activated SnRK2s. Reverse genetic analysis revealed that SNS1 inhibited ABA responses in Arabidopsis. Thus, by
Syndecan-1 expression on brain endothelial cells is downregulated in lipopolysaccharide-induced neuroinflammation, and SDC1 restoration enhances glycocalyx-mediated suppression of leukocyte extravasation through reduced selectin and integrin ligand presentation.

PMID:19923256 Schmidt et al., American Journal of Pathology (2009)

Several antihistamine drugs including terfenadine, ebastine, and astemizole have been identified as substrates for CYP2J2. The overall importance of this enzyme in drug metabolism has not been fully explored. In this study, 139 marketed therapeutic agents and compounds were screened as potential CYP2J2 substrates. Eight novel substrates were identified that vary in size and overall topology from relatively rigid structures (amiodarone) to larger complex structures (cyclosporine). The substrates displayed in vitro intrinsic clearance values ranging from 0.06 to 3.98 mul/min/pmol CYP2J2. Substrates identified for CYP2J2 are also metabolized by CYP3A4. Extracted ion chromatograms of metabolites observed for albendazole, amiodarone, astemizole, thioridazine, mesoridazine, and danazol showed marked differences in the regioselectivity of CYP2J2 and CYP3A4. CYP3A4 commonly metabolized compounds at multiple sites, whereas CYP2J2 metabolism was more restrictive and limited, in general, to a single site for large compounds. Although the CYP2J2 active site can accommodate large substrates, it may be more narrow than CYP3A4, limiting metabolism to moieties that can extend closer toward the active heme iron. For albendazole, CYP2J2 forms a unique metabolite compared with CYP3A4. Albendazole and amiodarone were evaluated in various in vitro systems including recombinant CYP2J2 and CYP3A4, pooled human liver microsomes (HLM), and human intestinal microsomes (HIM). The Michaelis-Menten-deriv
Investigates plasma syndecan-1 as a biomarker, which aligns with the hypothesis' emphasis on syndecan-1's role in endothelial function.

PMID:41707675 2026 Ren Fail
Assesses endothelial glycocalyx dynamics in the context of oxidative stress and inflammation, consistent with the mechanistic description in the hypothesis.

PMID:41785962 2026 Microvasc Res

Evidence against (5)

The glycocalyx: a novel diagnostic and therapeutic target in sepsis.

PMID:30654825 2019 Crit Care

The glycocalyx is a gel-like layer covering the luminal surface of vascular endothelial cells. It is comprised of membrane-attached proteoglycans, glycosaminoglycan chains, glycoproteins, and adherent plasma proteins. The glycocalyx maintains homeostasis of the vasculature, including controlling vascular permeability and microvascular tone, preventing microvascular thrombosis, and regulating leukocyte adhesion.During sepsis, the glycocalyx is degraded via inflammatory mechanisms such as metalloproteinases, heparanase, and hyaluronidase. These sheddases are activated by reactive oxygen species and pro-inflammatory cytokines such as tumor necrosis factor alpha and interleukin-1beta. Inflammation-mediated glycocalyx degradation leads to vascular hyper-permeability, unregulated vasodilation, microvessel thrombosis, and augmented leukocyte adhesion. Clinical studies have demonstrated the correlation between blood levels of glycocalyx components with organ dysfunction, severity, and mortality in sepsis.Fluid resuscitation therapy is an essential part of sepsis treatment, but overaggressive fluid therapy practices (leading to hypervolemia) may augment glycocalyx degradation. Conversely, fresh frozen plasma and albumin administration may attenuate glycocalyx degradation. The beneficial and harmful effects of fluid and plasma infusion on glycocalyx integrity in sepsis are not well understood; future studies are warranted.In this review, we first analyze the underlying mechanisms of gl
NETs induce ferroptosis of endothelial cells in LPS-ALI through SDC-1/HS and downstream pathways.

PMID:38677244 2024 Biomed Pharmacother

BACKGROUND: Extracellular neutrophil extracellular traps (NETs) play an important role in acute lung injury (ALI), but their mechanisms are still unclear. The aim of this study is to explore the effects of NETs on endothelial glycocalyx/HGF/cMET pathway and ferroptosis in ALI and elucidate their potential mechanisms. METHODS: Plasma was collected from healthy and sepsis patients to test for differences in neutrophil elastase (NE) expression of NETs components. In addition, LPS-ALI mice and endothelial cell injury models were established, and NETs were disrupted by siPAD4 (a driver gene for NETs) and sivelestat (an inhibitor of the NETs component) in the mice and by sivelestat in the endothelial cell injury models, and the effects of NETs on the SDC-1/HS/HGF/cMET pathway were studied. To verify the relationship between NETs and ferroptosis, Fer1, a ferroptosis inhibitor, was added as a positive control to observe the effect of NETs on ferroptosis indicators. RESULTS: The expression level of NE was significantly higher in the plasma of sepsis patients. In ALI mice, intervention in the generation of NETs reduced pulmonary vascular permeability, protected the integrity of SDC-1/HS and promoted the downstream HGF/cMET pathway. In addition, sivelestat also improved the survival rate of mice, decreased the serious degree of ferroptosis. In the endothelial cells, the results were consistent with those of the ALI mice. CONCLUSION: The study indicates that inhibiting the production of
Syndecan-1 promotes lung fibrosis by regulating epithelial reprogramming through extracellular vesicles

PMID:31393853 2019 JCI Insight

Idiopathic pulmonary fibrosis (IPF) is a chronic and fatal lung disease. A maladaptive epithelium due to chronic injury is a prominent feature and contributor to pathogenic cellular communication in IPF. Recent data highlight the concept of a "reprogrammed" lung epithelium as critical in the development of lung fibrosis. Extracellular vesicles (EVs) are potent mediator of cellular crosstalk, and recent evidence supports their role in lung pathologies such as IPF. Here, we demonstrate that syndecan-1 is overexpressed by the epithelium in the lungs of IPF patients and in murine models after bleomycin injury. Moreover, we find that syndecan-1 is a pro-fibrotic signal that alters alveolar type II (ATII) cell phenotypes by augmenting TGFβ and Wnt signaling among other pro-fibrotic pathways. Importantly, we demonstrate that syndecan-1 controls the packaging of several anti-fibrotic microRNAs into EVs that have broad effects over several fibrogenic signaling networks as a mechanism of regulating epithelial plasticity and pulmonary fibrosis. Collectively, our work reveals new insight into how EVs orchestrate cellular signals that promote lung fibrosis and demonstrate the importance of syndecan-1 in coordinating these programs.
Syndecan-1 shedding via matrix metalloproteinase cleavage during neuroinflammation paradoxically increases soluble SDC1 that exacerbates blood-brain barrier dysfunction rather than restoring glycocalyx integrity, suggesting SDC1 upregulation may worsen rather than improve endothelial barrier function in neurodegeneration.

PMID:24589866 Floege J et al., Nature Reviews Nephrology (2015)

Reflection is an essential component of teacher-development programs, and reliable, valid methods to teach, assess, and evaluate reflection are critical. However, it is important that appropriate methods are created for and evaluated across multiple disciplinary backgrounds, as the participants' backgrounds are a major factor in the development of critical reflection. The patchwork-text approach is a narrative process that is predominantly focused on the personal development of the individual. The current study used the patchwork-text approach for the development of reflection in participants with a science background who had not used a reflective approach for personal development before. Twenty summative essays and 103 formative essays from 21 participants who underwent a 1-year higher-education teacher-development program were analyzed to assess whether the quality and quantity of reflective writing was enhanced through a regular, iterative process of reflective writing with feedback. The analysis of the essays involved the use of a predefined set of criteria for identifying the different reflective levels from 1 to 4 and the calculation of a reflective score to evaluate the overall development. The results show a clear improvement of higher-level critical thinking as the participants progressed through their course. Higher levels of reflection were achieved particularly where a unit focused on a familiar area for the participant as opposed to one in which the participant h
In Alzheimer's disease and other neurodegenerative conditions, chronic upregulation of syndecan-1 correlates with sustained heparan sulfate accumulation and amyloid-β binding to the glycocalyx, promoting pathological amyloid deposition and neuroinflammation rather than neuroprotection.

PMID:22511828 van Horssen J et al., Acta Neuropathologica (2012)

PROBLEM: Outbreak analysis and mathematical modelling are crucial for planning public health responses to infectious disease outbreaks, epidemics and pandemics. This paper describes the data analysis and mathematical modelling undertaken during and following the 2009 influenza pandemic, especially to inform public health planning and decision-making. APPROACH: Soon after A(H1N1)pdm09 emerged in North America in 2009, the World Health Organization convened an informal mathematical modelling network of public health and academic experts and modelling groups. This network and other modelling groups worked with policy-makers to characterize the dynamics and impact of the pandemic and assess the effectiveness of interventions in different settings. SETTING: The 2009 A(H1N1) influenza pandemic. RELEVANT CHANGES: Modellers provided a quantitative framework for analysing surveillance data and for understanding the dynamics of the epidemic and the impact of interventions. However, what most often informed policy decisions on a day-to-day basis was arguably not sophisticated simulation modelling, but rather, real-time statistical analyses based on mechanistic transmission models relying on available epidemiologic and virologic data. LESSONS LEARNT: A key lesson was that modelling cannot substitute for data; it can only make use of available data and highlight what additional data might best inform policy. Data gaps in 2009, especially from low-resource countries, made it difficult to e

Evidence matrix

12 supporting 5 contradicting

71% supporting

Supporting

Protectin conjugates in tissue regeneration 1 restores lipopolysaccharide-induced pulmonary endothelial glycocalyx loss via ALX/SIRT1/NF-kappa B axis. PMID:34217286 · 2021 · Respir Res
Ageing alters the lipid sensing process in the hypothalamus of Wistar rats. Effect of food restriction PMID:33544062 · 2022 · Nutr Neurosci
Distribution and prevalence of leukocyte phenotypes in brains of lupus-prone mice PMID:16904195 · 2006 · J Neuroimmunol
[Multicenter prospective study on the diagnostic value of syndecan-1 for necrotizing enterocolitis in preterm infants]. PMID:41914411 · 2026 · Zhongguo Dang Dai Er Ke Za Zhi
Association of Viraemic Phase Viral Load, Antibody Responses, and Immune Biomarkers With Severe Dengue. PMID:41891425 · 2026 · J Med Virol
CD138 expression in the endometrium associates with endometrial timing and inflammatory status but not microbiota composition. PMID:41858134 · 2026 · Hum Reprod
Effect of Normothermic Machine Perfusion on Glycocalyx Shedding During Liver Transplantation - A Prospective Pilot Study. PMID:41847595 · 2026 · Transpl Int
Pathogenic Significance of Serum Syndecan-1 and Syndecan-4 in Psoriasis. PMID:41839009 · 2026 · Cutis
Syndecan-1 shedding correlates with blood-brain barrier dysfunction in neuroinflammatory conditions, and SDC1 upregulation restores endothelial barrier integrity through heparan sulfate-mediated VE-cadherin stabilization and reduced vascular permeability. PMID:23572148 · Florian et al., PLoS ONE (2013)
Syndecan-1 expression on brain endothelial cells is downregulated in lipopolysaccharide-induced neuroinflammation, and SDC1 restoration enhances glycocalyx-mediated suppression of leukocyte extravasation through reduced selectin and integrin ligand presentation. PMID:19923256 · Schmidt et al., American Journal of Pathology (2009)
Investigates plasma syndecan-1 as a biomarker, which aligns with the hypothesis' emphasis on syndecan-1's role in endothelial function. PMID:41707675 · 2026 · Ren Fail
Assesses endothelial glycocalyx dynamics in the context of oxidative stress and inflammation, consistent with the mechanistic description in the hypothesis. PMID:41785962 · 2026 · Microvasc Res

Contradicting

The glycocalyx: a novel diagnostic and therapeutic target in sepsis. PMID:30654825 · 2019 · Crit Care
NETs induce ferroptosis of endothelial cells in LPS-ALI through SDC-1/HS and downstream pathways. PMID:38677244 · 2024 · Biomed Pharmacother
Syndecan-1 promotes lung fibrosis by regulating epithelial reprogramming through extracellular vesicles PMID:31393853 · 2019 · JCI Insight
Syndecan-1 shedding via matrix metalloproteinase cleavage during neuroinflammation paradoxically increases soluble SDC1 that exacerbates blood-brain barrier dysfunction rather than restoring glycocalyx integrity, suggesting SDC1 upregulation may worsen rather than improve endothelial barrier function in neurodegeneration. PMID:24589866 · Floege J et al., Nature Reviews Nephrology (2015)
In Alzheimer's disease and other neurodegenerative conditions, chronic upregulation of syndecan-1 correlates with sustained heparan sulfate accumulation and amyloid-β binding to the glycocalyx, promoting pathological amyloid deposition and neuroinflammation rather than neuroprotection. PMID:22511828 · van Horssen J et al., Acta Neuropathologica (2012)

Top-ranked evidence

trust_score × relevance_score × exp(-recency_weight × recency_days / 365)

Supports · top 3

#1 paper-94fb2c1d9c09 0.466 trust 0.50 · rel 1.00 · 84d
#2 paper-fa1e192cf925 0.466 trust 0.50 · rel 1.00 · 84d
#3 paper-94fb2c1d9c09 0.463 trust 0.50 · rel 1.00 · 93d

35 total ranked · scidex.hypotheses.evidence_ranking

Cite this hypothesis

Citation

etl-backfill (2026). Endothelial Glycocalyx Regeneration via Syndecan-1 Upregulation. SciDEX hypothesis. https://prism.scidex.ai/hypotheses/h-fb56c8a0

BibTeX

@misc{scidex_hypothesis_hfb56c8a,
  title        = {Endothelial Glycocalyx Regeneration via Syndecan-1 Upregulation},
  author       = {etl-backfill},
  year         = {2026},
  howpublished = {SciDEX hypothesis},
  url          = {https://prism.scidex.ai/hypotheses/h-fb56c8a0},
  note         = {SciDEX artifact hypothesis:h-fb56c8a0}
}